Literature DB >> 11454653

Role of opioid receptors in neurogenic dural vasodilation and sensitization of trigeminal neurones in anaesthetized rats.

D J Williamson1, S L Shepheard, D A Cook, R J Hargreaves, R G Hill, M J Cumberbatch.   

Abstract

Migraine headache is thought to be caused by a distension of meningeal blood vessels, the activation of trigeminal sensory neurones and the the development of a central sensitization within the trigeminal nucleus caudalis (TNC). It has been proposed that clinically effective 5-HT(1B/1D) agonists act peripherally to inhibit the release of calcitonin gene-related peptide (CGRP) and neurogenic dural vasodilation, and to attenuate nociceptive neurotransmission within the TNC. Since opioids are also effective anti-migraine agents the present studies investigated the role of opioids within the trigemino-vascular system in anaesthetised rats. Electrical stimulation of the dura mater evoked neurogenic dural vasodilation which was significantly inhibited by morphine (1 mg kg(-1)) the selective mu-opioid agonist DAGO (10 microg kg(-1)) and the mixed agonist/antagonist butorphanol (1 mg kg(-1)) but not by the kappa- and delta-opioid agonists (+/-) U50488H (100 microg kg(-1)) and DPDPE (1 mg kg(-1)). Morphine had no effect on CGRP-evoked dural vasodilation. In electrophysiological studies morphine (1 - 10 mg kg(-1)) significantly attenuated brainstem neuronal activity in response to electrical stimulation of the dura by 65% at 10 mg kg(-1). Morphine (3 mg kg(-1)) also inhibited the TNC neuronal sensitization following CGRP-evoked dilation. The present studies have demonstrated that opioids block the nociceptive neurotransmission within the trigeminal nucleus caudalis and in addition inhibit neurogenic dural vasodilation via an action on mu-opioid receptors located on trigeminal sensory fibres innervating dural blood vessels. These peripheral and central actions are similar to those of the 'triptan' 5-HT(1B/1D) agonists and could account for the anti-migraine actions of opioids.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11454653      PMCID: PMC1572844          DOI: 10.1038/sj.bjp.0704136

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  34 in total

Review 1.  Methods used for the study of opioid receptors.

Authors:  F M Leslie
Journal:  Pharmacol Rev       Date:  1987-09       Impact factor: 25.468

Review 2.  Multiple opioid systems and pain.

Authors:  M J Millan
Journal:  Pain       Date:  1986-12       Impact factor: 6.961

3.  An association between migraine and cutaneous allodynia.

Authors:  R Burstein; D Yarnitsky; I Goor-Aryeh; B J Ransil; Z H Bajwa
Journal:  Ann Neurol       Date:  2000-05       Impact factor: 10.422

4.  Ergot alkaloids block neurogenic extravasation in dura mater: proposed action in vascular headaches.

Authors:  K Saito; S Markowitz; M A Moskowitz
Journal:  Ann Neurol       Date:  1988-12       Impact factor: 10.422

Review 5.  Pharmacology of opioids.

Authors:  W R Martin
Journal:  Pharmacol Rev       Date:  1983-12       Impact factor: 25.468

6.  The binding spectrum of narcotic analgesic drugs with different agonist and antagonist properties.

Authors:  J Magnan; S J Paterson; A Tavani; H W Kosterlitz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1982-06       Impact factor: 3.000

7.  Localization of kappa-opioid receptor mRNA in neuronal subpopulations of rat sensory ganglia and spinal cord.

Authors:  M K Schäfer; M Bette; H Romeo; W Schwaeble; E Weihe
Journal:  Neurosci Lett       Date:  1994-02-14       Impact factor: 3.046

Review 8.  Neurovascular and molecular mechanisms in migraine headaches.

Authors:  M A Moskowitz; R Macfarlane
Journal:  Cerebrovasc Brain Metab Rev       Date:  1993

Review 9.  Neurogenic versus vascular mechanisms of sumatriptan and ergot alkaloids in migraine.

Authors:  M A Moskowitz
Journal:  Trends Pharmacol Sci       Date:  1992-08       Impact factor: 14.819

10.  Comparative pharmacological and biochemical studies between butorphanol and morphine.

Authors:  P J Horan; I K Ho
Journal:  Pharmacol Biochem Behav       Date:  1989-12       Impact factor: 3.533

View more
  14 in total

1.  Muscarinic acetylcholine receptor modulation of mu (mu) opioid receptors in adult rat sphenopalatine ganglion neurons.

Authors:  Wojciech Margas; Saifeldin Mahmoud; Victor Ruiz-Velasco
Journal:  J Neurophysiol       Date:  2009-11-04       Impact factor: 2.714

2.  Effects of ionotropic glutamate receptor antagonists on rat dural artery diameter in an intravital microscopy model.

Authors:  K Y Chan; S Gupta; R de Vries; A H J Danser; C M Villalón; E Muñoz-Islas; A Maassenvandenbrink
Journal:  Br J Pharmacol       Date:  2010-07       Impact factor: 8.739

3.  [The role of opioids in the treatment of primary headache disorders].

Authors:  A Totzeck; C Gaul
Journal:  Schmerz       Date:  2014-04       Impact factor: 1.107

4.  Topiramate inhibits trigeminovascular activation: an intravital microscopy study.

Authors:  Simon Akerman; Peter J Goadsby
Journal:  Br J Pharmacol       Date:  2005-09       Impact factor: 8.739

5.  5-HT7 receptors are involved in neurogenic dural vasodilatation in an experimental model of migraine.

Authors:  Xiaojuan Wang; Yannan Fang; Jianbo Liang; Miansheng Yan; Rong Hu; Xiaoping Pan
Journal:  J Mol Neurosci       Date:  2014-03-02       Impact factor: 3.444

6.  Voltage-dependent calcium channels are involved in neurogenic dural vasodilatation via a presynaptic transmitter release mechanism.

Authors:  S Akerman; D J Williamson; P J Goadsby
Journal:  Br J Pharmacol       Date:  2003-08-26       Impact factor: 8.739

Review 7.  Animal migraine models for drug development: status and future perspectives.

Authors:  Inger Jansen-Olesen; Peer Tfelt-Hansen; Jes Olesen
Journal:  CNS Drugs       Date:  2013-12       Impact factor: 5.749

8.  Characterization of opioid receptors that modulate nociceptive neurotransmission in the trigeminocervical complex.

Authors:  R J Storer; S Akerman; P J Goadsby
Journal:  Br J Pharmacol       Date:  2003-01       Impact factor: 8.739

9.  CGRP function-blocking antibodies inhibit neurogenic vasodilatation without affecting heart rate or arterial blood pressure in the rat.

Authors:  J Zeller; K T Poulsen; J E Sutton; Y N Abdiche; S Collier; R Chopra; C A Garcia; J Pons; A Rosenthal; D L Shelton
Journal:  Br J Pharmacol       Date:  2008-09-08       Impact factor: 8.739

Review 10.  Opioid resistance in chronic daily headache: a synthesis of ideas from the bench and bedside.

Authors:  David M Biondi
Journal:  Curr Pain Headache Rep       Date:  2003-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.